Vnitr Lek 2025, 71(1):24-26 | DOI: 10.36290/vnl.2025.004

Allopurinol and uricosurics

Jiří Slíva
Ústav farmakologie, 3. LF UK, Praha

The presented text briefly characterizes the basic possibilities of pharmacotherapeutic treatment of hyperuricemia. Allopurinol acting as a competitive xanthine oxidase inhibitor with a potential for use beyond the mere influence of uricemia is still the most commonly used active substance in this indication. Other substances are also briefly mentioned, although many of them are not currently available in the Czech Republic.

Keywords: hyperuricaemia, allopurinol, xanthine oxidase, uricosurics, antiuratics, uricase.

Accepted: February 6, 2025; Published: February 18, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Allopurinol and uricosurics. Vnitr Lek. 2025;71(1):24-26. doi: 10.36290/vnl.2025.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benn CL, Dua P, Gurrell R, et al. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne). 2018 May 31;5:160. Go to original source... Go to PubMed...
    2. Graham GG, Kannangara DR, Stocker SL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol. 2013 Dec;76(6):932-8. Go to original source... Go to PubMed...
    3. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623-44. Go to original source... Go to PubMed...
    4. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999 Oct;48(4):501-9. Go to original source... Go to PubMed...
    5. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010 Sep 2;363(10):954-63. Go to original source... Go to PubMed...
    6. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005 Mar 4;76(16):1835-47. Go to original source... Go to PubMed...
    7. Robinson PC, Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018 Aug;19(11):1289-1299. Go to original source... Go to PubMed...
    8. Bardin T, Richette P. The role of febuxostat in gout. Curr Opin Rheumatol. 2019 Mar;31(2):152-158. Go to original source... Go to PubMed...
    9. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1111-6. Go to original source... Go to PubMed...
    10. Khosravan R, Kukulka MJ, Wu JT, et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008 Sep;48(9):1014-24. Go to original source... Go to PubMed...
    11. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.